Vision Group offers a full spectrum of eye care with its network of laser refractive and intraocular surgical facilities, public cataract contracts, and ophthalmology clinics. Self-described as having experienced physicians and state-of-the-art technology.

Vision Group

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

S Nikhil Kumar

AbbVie Inc.

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Bernard Chauvin

Bausch + Lomb Corporation

CooperVision is a company that manufactures and sells contact lenses and related products.

Metric
Company Name	Vision Group	AbbVie Inc.	Bausch + Lomb Corporation	CooperVision
Symbol		ABBV	BLCO
MSH ID	COM:THEVISIONGROUP	COM:ABBVIE	COM:BAUSCH	COM:COOPERVISION
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare & Health Services
Industry	Healthcare	Drug Manufacturers - General	Medical - Instruments & Supplies	Medical Devices and Supplies
Country	US	US	CA	US
Stage
Employee Count		50K	13.30K	10.00K
Website	thevisiongroup.com	abbvie.com	bausch.com	coopervision.com
LinkedIn
Founders

Metric
Market Cap	296.91B	5.43B
Enterprise Value
Monthly Web Traffic	1.18M		402.65K
Web Traffic Growth	0.51		0.33
Valuation
Raised Capital	15B

Metric
Revenue	54.32B	4.15B
Revenue (LTM)
Revenue (NTM)
Gross Profit	45.54B	2.50B
EBITDA	18.10B	601M
Operating Income	17.43B	130M
Net Income	4.86B	-260M
EPS	2.75	-0.74
Diluted EPS	2.74	-0.74
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.72	0.96
Operating Profit Margin	0.27	0.12
EBITDA Margin	0.33	0.14
Net Profit Margin	0.11	-0.00
Return on Equity	0.57	0.02
Return on Assets	0.04	-0.00
Return on Capital Employed	0.15	0.05

COM:THEVISIONGROUP

Vision Group

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	46.58	-23.54
P/B Ratio	25.09	0.71
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.36	1.64
EV Multiple	17.44	17.67

Metric
Days Sales Outstanding	75.54	72.01
Days Payables Outstanding		82.99
Days Inventory Outstanding	102.41	1.62K
Operating Cycle	181.71	1.70K
Cash Conversion Cycle	179.57	1.07K
Asset Turnover	0.40	0.34

Metric
Operating Cash Flow	22.84B	-17M
Free Cash Flow	22.06B	-198M
Cash Flow to Debt	0.38	0.05
Operating Cash Flow/Sales	0.42	0.13
Free Cash Flow Yield	0.08	-0.00

Metric
Cash & Equivalents	12.81B	331M
Accounts Receivable	66M	-121M
Inventory	4.10B	1.03B
Goodwill	32.29B	4.58B
Debt to Capitalization	0.91	1.05
Debt to Assets	0.45	0.34
Current Ratio	0.96	1.78
Quick Ratio	0.83	1.03

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.02
R&D to Revenue	0.14	0.08
SG&A to Revenue